Save up -80% on Efavirenz
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Sustiva
|$323.45||30 capsules/600 mg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Efavirenz coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Efavirenz every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Efavirenz volume of distribution
Oral volume of distribution is 252 L
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Efavirenz
Efavirenz (brand names Sustiva and Stocrin) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Efavirenz mechanism of action
Similar to zidovudine, efavirenz inhibits the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). Antiviral activity of efavirenz is dependent on intracellular conversion to the active triphosphorylated form. The rate of efavirenz phosphorylation varies, depending on cell type. It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body. Even though human DNA polymerase is less susceptible to the pharmacologic effects of triphosphorylated efavirenz, this action may nevertheless account for some of the drug’s toxicity.
Dosage forms of Efavirenz
A S Medication Solutions
Human Immunodeficiency Virus
Indication of Efavirenz
For use in combination treatment of HIV infection (AIDS)
Toxicity of Efavirenz
The risk for toxicity has been associated with loss of function polymorphisms of cytochrome 2B6, the main metabolising enzyme for EFV.7 It is estimated that about 20% of sub-Saharan Africans are genetically slow metabolisers and may be at risk of EFV toxicity. Efavirenz toxicity should be considered in patients who present with depression, psychosis, catatonia, encephalopathy or ataxia after the first few weeks of therapy when other causes are excluded.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Efavirenz on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.